| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.6 | -3.9 |
| EPS (diluted, $ a share) | $-0.24 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: INAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
In8Bio, Inc.: key numbers
- Share price
- $0.8160Close, Nov 16
- Market cap
- $8.82M
- Shares outstanding
- 10.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from In8Bio, Inc.
All →In8Bio Financial Results
IN8bio reported financial results for the third quarter of 2026, highlighting the appointment of Dr. Oxana Polyakova as SVP of R&D and progress in its gamma-delta T cell engager platform. The company remains on track to report initial in vivo preclinical data for its INB-619 program by the end of 2026.
- Term
- Q3 2026
“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform. It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”
William Ho, CEO and co-founder of IN8bio